Related Experiment Video
Updated: Jun 21, 2026
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
Published on: August 1, 2013
Development of an effective method for dendritic cell immunotherapy of mouse melanoma
1Department of Dermatology, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea.
Abstract:
Dendritic cell (DC) immunotherapy is a strong candidate for the treatment of incurable cancers especially malignant melanoma. Nevertheless, the proper guideline of DC immunotherapy does not exist. The absence of the guideline is also an obstacle to clinical trials of DC immunotherapy. So we conducted this study in order to develop an effective DC preparation method for immunotherapy in mouse malignant melanoma. Mouse bone marrow-derived DC were stimulated with tumour antigen alone or tumour antigen plus a cocktail (anti-CD40 antibody +TNF-alpha+ IL-1beta) for 8, 24 or 48 h and the characteristics of these DC, such as surface molecules (CD40, CD80, CD86, MHC class II, CCR7), cytokines(IL-12, IFN-gamma, and IL-10), DC-induced T cell proliferation in vitro, and the production of IFN-gamma by those cells, were evaluated. Mice with melanoma were then treated with DC stimulated with tumour antigen alone and tumour antigen plus cocktail for 8 or 48 h. The tumour size and survival rate of these mice were then evaluated. (1) Beneficial clinical effects such as a reduction of tumour size and an increased survival rate were best observed in the group treated with DC stimulated for 8 h with tumour antigen plus cocktail. (2) The single prominent characteristic of DC stimulated for 8 h with tumour antigen plus cocktail was an elevated IL-12 secretion. The cytokine IL-12 was not secreted by other DC. Consequently, proper production of IL-12 was found to be an important requirement for DC used in immunotherapy of mouse melanoma.
Insights
Developing effective dendritic cell (DC) immunotherapy for melanoma requires optimal preparation. Stimulating DCs with tumor antigen and a cocktail for 8 hours, enhancing IL-12 secretion, significantly reduced tumor size and improved survival in mice.
Area of Science:
- Immunology
- Cancer Research
- Biotechnology
Background:
- Dendritic cell (DC) immunotherapy shows promise for treating cancers like malignant melanoma.
- Current lack of standardized DC preparation guidelines hinders clinical trials.
- Effective DC preparation is crucial for successful cancer immunotherapy.
Purpose of the Study:
- To develop an optimized method for preparing dendritic cells (DCs) for immunotherapy in a mouse model of malignant melanoma.
- To evaluate the impact of different stimulation conditions on DC characteristics and anti-tumor efficacy.
Main Methods:
- Mouse bone marrow-derived DCs were stimulated with tumor antigen alone or with a cocktail (anti-CD40 antibody, TNF-alpha, IL-1beta) for varying durations (8, 24, 48 hours).
- DC characteristics including surface molecules, cytokine production (IL-12, IFN-gamma, IL-10), and T cell proliferation were assessed.
- Mice with melanoma were treated with prepared DCs, and tumor size and survival rates were evaluated.
Main Results:
- DCs stimulated for 8 hours with tumor antigen plus the cocktail demonstrated the most significant anti-tumor effects, reducing tumor size and increasing survival.
- The key characteristic of these effective DCs was elevated Interleukin-12 (IL-12) secretion, which was not observed with other stimulation methods.
- IL-12 production by DCs was identified as a critical factor for successful immunotherapy in this melanoma model.
Conclusions:
- Optimized DC preparation, specifically 8-hour stimulation with tumor antigen and a cocktail, enhances anti-melanoma efficacy.
- Elevated IL-12 secretion is a crucial marker and requirement for effective DC immunotherapy.
- This study provides a foundation for developing standardized DC preparation protocols for melanoma treatment.
